Bedside trial of COVID-19 ICU patients sees hydrocortisone improve recovery
- Researchers have found that intravenous hydrocortisone improves recovery and survival for critically ill COVID-19 patients.
- The finding comes as a result of the REMAP-CAP trial that was set up by a group of intensive care specialists from around the world to future-proof for pandemics like COVID-19.
- COVID-19 patients from more than 200 intensive care units around the world have been part of this adaptive randomised trial.
A global study, led from Monash University, has found that delivering intravenous hydrocortisone, a corticosteroid, improves recovery and survival for critically ill COVID-19 patients.
In March 2020, the REMAP-CAP investigators, led by intensive care clinician Professor Steve Webb from Monash University’s School of Public Health and Preventive Medicine, began randomising patients with COVID-19 to alternative hydrocortisone dosing strategies compared with patients who received no corticosteroid.
Involving 384 adult participants globally, the researchers found a 93 per cent probability that administration of hydrocortisone improved recovery and survival. These results build on the success of existing evidence involving dexamethasone, another corticosteroid, substantiating that this class of anti-inflammatory drugs can make a real difference in the fight against COVID-19.
Read the full story here.